MA-REINVEST-ROBOTICS
8.12.2021 13:02:06 CET | Business Wire | Press release
The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics , the VDMA Robotics + Automation Association , EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals.
While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted:
- The mandatory third-party certification requirements will slow tech innovation across Europe.
- The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage globally.
- Disruption risk to regional supply chain, manufacturing and logistics operations will rise if the proposals are implemented and adopted.
- Compliance with regulation worldwide will become more complex and burdensome.
Dr. Susanne Bieller, General Secretary of the International Federation of Robotics, states, “The International Federation of Robotics calls on European policymakers to amend both drafts to balance the protection of citizens with the market’s need to adopt new technologies and ensure a level-playing field for companies. This is not purely a European issue, as the proposed regulations will severely impact all companies bringing robots to the European market. In the long run, the new regulations will be to the disadvantage of European companies, especially SMEs and startups.”
Patrick Schwarzkopf, Managing Director of the VDMA Robotics + Automation Association and Director of EUnited Robotics, comments: “The EU-Commission’s proposals include burdensome regulations of so-called ‘High-Risk AI’ and ‘High-Risk-machinery.’ They include the introduction of extensive mandatory third-party certification requirements, which will discourage the use of AI and slow down innovation across Europe.”
Dr. Esben Hallundbæk Østergaard, the CEO of REInvest Robotics and founder of Universal Robots, comments: “The proposed legislation will hold back European robotics innovation. This is particularly concerning given robotics is the one emerging tech segment where Europe still has an edge globally. Locally, the legislation will negatively affect thousands of small businesses, factories, and manufacturers that rely on robotics and AI to automate critical operations and overcome labor shortages.”
Recommended policy amendments include limiting the scope of the AI Act to essential human rights risks, relying on manufacturers’ self-declaration of conformity in both the AI-Act and Regulation on Machinery Products, increasing enforcement and governance of the existing approach of the machinery directive, and working to create a global framework that increases safety and ethics while maintaining a level playing field. The recent draft report published on the Regulation on Machinery products by the European Parliament’s Committee on Internal Market and Consumer Protection (IMCO) points in this direction by proposing to uphold the crucial principle of self-declaration.
“The approach of the current machinery directive is sufficient. The problem is with governance. We recommend focusing on ensuring that products on the market actually comply with the current EU law, not creating new regulations,” said Østergaard.
For more info, visit reinvestrobotics.com and watch Patrick Schwarzkopf and Dr. Esben Hallundbæk Østergaard discuss the proposals: https://youtu.be/cd0VQx6w-wQ
About REInvest Robotics
REInvest Robotics is a specialized accelerator that invests in startups that democratize the use of robotics to solve real world problems. Founded by robotics pioneer and inventor Esben Hallundbæk Østergaard and Richa Hallundbæk Misri, REInvest Robotics’ vision is to fuel the robotics ecosystem with sustainable investments and help entrepreneurs uplift humankind through robotics. The firm – which provides seed funding and advisory services – specializes in robotics, AI, manufacturing, safety standards and legislation. Successful investments include market leaders Universal Robots and Mobile Industrial Robots (MiR). Learn more at https://www.reinvestrobotics.com/ and follow REInvest Robotics on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
